Technology

Clinical Genomics owns gene expression biomarkers for both RNA and methyl-DNA assays that have been validated in independent clinical specimens to be sensitive and specific for the earliest stages of cancer, including potentially dangerous precancerous lesions.  Clinical Genomics is working with our scientific, clinical and commercial collaborators to deliver a blood-based diagnostic test for colorectal neoplasia based on our proprietary technologies.

To support clinical assay product development, Clinical Genomics has developed a range of ancillary technologies primarily aimed at rapidly and efficiently bridging the gap between patient specimen collection and molecular testing.  These technologies include novel approaches to plasma processing to yield nucleic acids for testing, as well as an innovative device to fractionate rare cells and molecules from complex specimens such as blood.

To maximize the commercial potential of this product Clinical Genomics has partnered with the largest clinical diagnostic lab company in the world, Quest Diagnostics. By delivering a more accurate diagnosis and screening method for early colorectal cancer detection, such a product will place Clinical Genomics at the forefront of an emerging and highly valuable market in molecular clinical diagnostics.